Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe
Nanox (NASDAQ: NNOX) announced that its subsidiary Nanox AI will present new data from the ADOPT study at four major medical conferences across Europe from March to June 2025. The study, completed in February 2025, evaluated HealthVCF at four NHS trusts in the UK.
Key findings show that HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new asymptomatic patients with vertebral compression fractures - up to six times more than the national NHS average. The AI-enabled Fracture Liaison Services demonstrated up to 10% reduction in patient refracture rates and cost savings of up to £50,000 per healthcare organization.
The company's newer FDA-cleared solution, HealthOST, offers improved fracture measurement precision and can detect low bone mineral density in routine CT scans without additional imaging or radiation exposure.
Nanox (NASDAQ: NNOX) ha annunciato che la sua filiale Nanox AI presenterà nuovi dati dallo studio ADOPT in quattro importanti conferenze mediche in Europa da marzo a giugno 2025. Lo studio, completato a febbraio 2025, ha valutato HealthVCF in quattro trust NHS nel Regno Unito.
I risultati chiave mostrano che HealthVCF ha analizzato 37.220 TC mediche di routine e ha identificato oltre 3.450 nuovi pazienti asintomatici con fratture vertebrali - fino a sei volte in più rispetto alla media nazionale NHS. I servizi di liaison per le fratture abilitati dall'AI hanno dimostrato una riduzione fino al 10% nei tassi di rifrattura dei pazienti e risparmi sui costi fino a 50.000 sterline per ogni organizzazione sanitaria.
La nuova soluzione approvata dalla FDA dell'azienda, HealthOST, offre una maggiore precisione nella misurazione delle fratture e può rilevare una bassa densità minerale ossea nelle TC di routine senza necessità di ulteriori immagini o esposizione a radiazioni.
Nanox (NASDAQ: NNOX) anunció que su filial Nanox AI presentará nuevos datos del estudio ADOPT en cuatro importantes conferencias médicas en Europa desde marzo hasta junio de 2025. El estudio, completado en febrero de 2025, evaluó HealthVCF en cuatro trusts del NHS en el Reino Unido.
Los hallazgos clave muestran que HealthVCF analizó 37,220 tomografías computarizadas médicas de rutina e identificó a más de 3,450 nuevos pacientes asintomáticos con fracturas por compresión vertebral, hasta seis veces más que el promedio nacional del NHS. Los servicios de enlace de fracturas habilitados por IA demostraron una reducción de hasta el 10% en las tasas de refractura de pacientes y ahorros de costos de hasta £50,000 por organización de atención médica.
La nueva solución aprobada por la FDA de la empresa, HealthOST, ofrece una mayor precisión en la medición de fracturas y puede detectar baja densidad mineral ósea en tomografías computarizadas de rutina sin necesidad de imágenes adicionales o exposición a radiación.
Nanox (NASDAQ: NNOX)는 자회사 Nanox AI가 2025년 3월부터 6월까지 유럽의 네 개 주요 의료 회의에서 ADOPT 연구의 새로운 데이터를 발표할 것이라고 발표했습니다. 이 연구는 2025년 2월에 완료되었으며, 영국의 네 개 NHS 트러스트에서 HealthVCF를 평가했습니다.
주요 결과는 HealthVCF가 37,220건의 일상적인 의료 CT 스캔을 분석하고 3,450명 이상의 무증상 환자와 척추 압박 골절을 식별했음을 보여줍니다 - 이는 국가 NHS 평균의 최대 6배에 해당합니다. AI 기반의 골절 연계 서비스는 환자의 재골절률을 최대 10% 감소시키고 의료 기관당 최대 £50,000의 비용 절감을 보여주었습니다.
회사의 최신 FDA 승인 솔루션인 HealthOST는 골절 측정의 정확성을 향상시키고 추가 이미징이나 방사선 노출 없이 일상적인 CT 스캔에서 낮은 뼈 미네랄 밀도를 감지할 수 있습니다.
Nanox (NASDAQ: NNOX) a annoncé que sa filiale Nanox AI présentera de nouvelles données de l'étude ADOPT lors de quatre grandes conférences médicales en Europe de mars à juin 2025. L'étude, achevée en février 2025, a évalué HealthVCF dans quatre trusts NHS au Royaume-Uni.
Les résultats clés montrent que HealthVCF a analysé 37 220 tomodensitométries médicales de routine et a identifié plus de 3 450 nouveaux patients asymptomatiques avec des fractures vertébrales - jusqu'à six fois plus que la moyenne nationale du NHS. Les services de liaison pour les fractures activés par l'IA ont montré une réduction de jusqu'à 10 % des taux de refracture des patients et des économies de coûts allant jusqu'à 50 000 £ par organisation de santé.
La nouvelle solution approuvée par la FDA de l'entreprise, HealthOST, offre une précision améliorée dans la mesure des fractures et peut détecter une faible densité minérale osseuse dans les tomodensitométries de routine sans imagerie supplémentaire ni exposition aux radiations.
Nanox (NASDAQ: NNOX) gab bekannt, dass ihre Tochtergesellschaft Nanox AI neue Daten aus der ADOPT-Studie auf vier großen medizinischen Konferenzen in Europa von März bis Juni 2025 präsentieren wird. Die Studie, die im Februar 2025 abgeschlossen wurde, bewertete HealthVCF an vier NHS-Trusts im Vereinigten Königreich.
Wichtige Ergebnisse zeigen, dass HealthVCF 37.220 routinemäßige medizinische CT-Scans analysierte und über 3.450 neue asymptomatische Patienten mit Wirbelkörperfrakturen identifizierte - bis zu sechsmal mehr als der nationale NHS-Durchschnitt. Die KI-gestützten Frakturliaisondienste zeigten eine Reduzierung der Refrakturraten um bis zu 10% und Kosteneinsparungen von bis zu 50.000 £ pro Gesundheitseinrichtung.
Die neuere von der FDA zugelassene Lösung des Unternehmens, HealthOST, bietet eine verbesserte Präzision bei der Frakturmessung und kann eine niedrige Knochendichte in routinemäßigen CT-Scans ohne zusätzliche Bildgebung oder Strahlenexposition erkennen.
- AI solution detected 6x more vertebral compression fractures than national average
- Achieved 10% reduction in patient refracture rates
- Generated £50,000 cost savings per healthcare organization
- New FDA-cleared HealthOST solution offers enhanced capabilities
- None.
Insights
Nanox's AI bone solution is demonstrating significant clinical value in real-world healthcare settings. The ADOPT study results reveal the AI technology identified over 3,450 new patients with vertebral compression fractures from 37,220 CT scans—detecting up to six times more cases than the national average at NHS hospitals. This substantial improvement in detection rates addresses a critical gap in identifying asymptomatic patients.
The economic data is particularly compelling, showing AI-enabled services led to
FDA clearance for their newer HealthOST solution, which enhances fracture measurement precision and can identify low bone mineral density in routine CT scans without additional radiation exposure, positions Nanox competitively in the bone health AI market. Upcoming presentations at four major medical conferences across Europe represent important visibility opportunities to accelerate clinical adoption among potential customers. With osteoporosis affecting hundreds of millions globally, these study results demonstrate Nanox's AI technology can meaningfully impact early detection rates while delivering measurable healthcare economics benefits.
ADOPT Study Findings Highlight Nanox.AI’s Role in Enhancing Fracture Detection and Healthcare Cost Savings
PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study at four major upcoming medical conferences spanning March through June 2025.
The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and Southampton – coordinated by the long-standing clinical users at Oxford. In earlier findings from the ADOPT study, HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new patients with vertebral compression fractures, up to six times more than the national average at NHS hospitals in the UK. These patients were asymptomatic, and the early data underscores the importance of addressing the critical gap in detection of patients with vertebral fractures.
Kassim Javaid, Professor of Osteoporosis and Adult Rare Bone Diseases and lead investigator of the ADOPT study, will present expanded data from the study showcasing the clinical utility of the AI bone solution in assessing bone health and identifying key indicators of osteoporosis, along with the benefits of various approaches to its implementation and the effect it can have on the rate of patient detection. The presented data will also show the economic benefit that such AI tools can bring to a healthcare organization. The ADOPT study has shown that AI-enabled Fracture Liaison Services, together with other improvements, led to a reduction in patient refracture rates of up to
A more recent version of the AI bone solution, HealthOST, is FDA-cleared and was developed by Nanox AI following the initiation of the ADOPT study. HealthOST features improved precision in measuring fractures and the new ability to highlight low bone mineral density in routine CT scans, without requiring additional imaging or radiation exposure for the patient.
“These conferences provide an important opportunity to share our growing body of evidence supporting the clinical value of AI in transforming bone health assessment,” said Orit Wimpfheimer, M.D., Chief Medical Officer of Nanox. “With osteoporosis affecting hundreds of millions worldwide, our AI solution is demonstrating the potential to significantly improve early detection rates and enhance patient care pathways.”
The upcoming conferences are as follows:
British Institute of Radiology AI Congress
Date: March 27-28, 2025
Location: London, England
WCO-IOF-ESCEO Congress
Date: April 10-13, 2025
Location: Rome, Italy
European Calcified Tissue Society (ECTS) Congress
Date: May 23-26, 2025
Location: Innsbruck, Austria
Bone Research Society Annual Meeting
Date: June 25-27, 2025
Location: Edinburgh, Scotland
For more information on the ADOPT study, please visit Oxford’s ADOPT study website.
About Nanox AI
Nanox.AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox AI’s solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox.AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X-ray source.
Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for more accurate diagnostics and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source digital tomosynthesis system that is cost-effective and user-friendly; Nanox.AI LTD, a subsidiary of Nanox Imaging, with an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision.
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
FAQ
What were the key results of Nanox (NNOX) ADOPT study in 2025?
How many NHS trusts participated in Nanox's (NNOX) ADOPT study?
What are the differences between Nanox's HealthVCF and HealthOST solutions?
Which medical conferences will Nanox (NNOX) present its ADOPT study results at in 2025?
